TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Acetylcarnitine and Insulin Sensitivity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~at least three of these~* Relatives with type 2 diabetes~* Age between 40 and 65 years~* Systolic and diastolic pressure ≥ 140 or ≥90 mmHg respectively~* Body mass index ≥25 for men and ≥24 for women~* Triglycerides ≥200 mg/dl~* Serum creatinine ≤1.5 mg/dl, proteinuria ≤ 0.5g/24h~* Capacity to understand the scope and the risks of the study~* written informed consent~Exclusion Criteria:~* Concomitant treatment with steroids, anti-inflammatory and immunosuppressive drug, and any other drug acting on insulin sensitivity and/or insulin secretion, particularly glitazones and other oral hypoglycemic drug~* Treatment with L-acetylcarnitine in the six months before the study~* Previous or concomitant treatment with metformin~* legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- L-acetylcarnitine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation of nirmatrelvir/ritonavir treatment with patient-reported 100% compliance. Symptom alleviation or resolution in COVID-19 signs/symptoms followed by a worsening (rebound) of signs/symptoms after completing an initial 5-day course of nirmatrelvir/ritonavir~* Onset of rebound in COVID-19 symptoms within 2 weeks (14 days) after the completion of the initial 5-day course of nirmatrelvir/ritonavir.~* Onset of rebound in signs/symptoms attributable to COVID-19 within 48 hours prior to randomization and ≥1 sign/symptom attributable to COVID-19 present on the day of randomization.~* SARS-CoV-2 infection as determined by rapid antigen testing within 24 hours prior to randomization~* At least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19.~Exclusion Criteria:~* Current need for hospitalization, hospitalized for the COVID-19 infection or anticipated need for hospitalization within 24 hours after randomization~* History of severe chronic liver disease~* Receiving dialysis or have known age-specific estimated glomerular filtration rate (eGFR) or estimated creatinine clearance (eCrCl) \<30 mL/min/1.73 m2 at screening as measured by a serum creatinine point of care device~* Oxygen saturation of \<92% on room air obtained at rest within 24 hours prior to randomization~* Immunocompromised.~* Current use of any prohibited concomitant medication(s)~* Females who are pregnant and \<14 weeks gestation

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nirmatrelvir plus ritonavir for 5 days (Type: EXPERIMENTAL): Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days
- placebo plus ritonavir for 5 days (Type: OTHER): placebo (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy volunteers:~1. Must be 18 years of age or older.~2. Must have no known medical problems and have had a full medical exam within 6 months of the study. If healthy volunteers have not had a full medical exam within 6 months of the study, one of the nuclear medicine physicians will conduct the medical exam prior to any study procedures.~3. Must understand and voluntarily have signed an Informed Consent after its contents have been fully explained.~4. Women of child bearing potential (as defined as women who are not post menopausal for 12 months or who have had no previous surgical sterilization) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 30 days after the last dose.~Pancreatic cancer subjects:~1. Participant must be 18 years or older at the time of radiotracer administration~2. Provides written informed consent~3. Suspected or established diagnosis of pancreatic cancer based on any radiographic scan or pathology and who is scheduled for surgery OR Biopsy proven diagnosis of pancreatic cancer who is no longer a surgical candidate~Exclusion Criteria:~Healthy volunteers:~1. Participant is less than 18 year-old~2. Pregnant or breast feeding women.~3. Patients who are not likely to comply with the protocol requirements.~Pancreatic cancer subjects:~1. Participant is pregnant or breast-feeding~2. Participant is not able to comply with the study procedures~3. Participant has serious uncontrolled concurrent medical illness that would limit compliance with study requirements~4. Metallic implants (contraindicated for MRI)~5. History of renal insufficiency (only for MRI contrast administration)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- pancreatic cancer patients (Type: EXPERIMENTAL): Patients receive \[18F\]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
- healthy patients (Type: EXPERIMENTAL): Patients receive \[18F\]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF defined as: with 2 CF-causing mutations, chronic sinopulmonary disease or gastrointestinal/nutritional abnormalities~* Subjects who weigh ≥15 kg without shoes at Screening Visit~* Subjects who are homozygous for the F508del-CFTR mutation~* Subjects with percent predicted forced expiratory volume in 1 second (FEV1) of 70% to 105% (inclusive) (Part A) or ≥40% (Part B) at Screening Visit where the predicted values are adjusted for age, sex, and height using the Wang equation~* Subjects with stable CF disease and who are willing to remain on stable CF medication regimen~* Able to swallow tablets~Exclusion Criteria:~* History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject~* Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before Day 1 of the study~* Abnormal liver function as defined in the protocol at Screening Visit~* Abnormal renal function as defined in the protocol at Screening Visit~* History of solid organ or hematological transplantation~* Ongoing participation in an investigational drug study or prior participation in an investigational drug study within 30 days prior of Screening Visit~* History or evidence of lens opacity or cataract at Screening Visit~* Colonization with organisms associated with a more rapid decline in pulmonary status at Screening Visit (Part A only)~* A standard 12-lead ECG demonstrating QTcF \>450 msec at Screening Visit

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Lumacaftor/Ivacaftor (LUM/IVA) (Type: EXPERIMENTAL): Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postprandial Effects of Walnut Components Versus Whole Walnuts on Cardiovascular Disease (CVD) Risk Reduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 21 - 60 years~* Body mass index 25-39 kg/m2~* LDL cholesterol \>110 mg/dL~* \<95 percentile for age and gender for both (based on NHANES data)~* TG \< 350 mg/dL~Exclusion Criteria:~* High alcohol consumption \> 21 units/week (female subjects) or \> 28 units/week (male subjects)~* Intake of vitamin and mineral supplements within the past 3 weeks or unwillingness to discontinue for 3 weeks prior to screening and for entire study.~* Use of prescription cholesterol-lowering or blood pressure-lowering medications during the study~* Intake of other putative cholesterol-lowering supplements (excl. psyllium, fish oil capsules, soy lecithin, phytoestrogens)~* Intake of anti-inflammatory medications (containing aspirin or NSAIDS) on a regular basis or if an acute intake, within 48 hours of a test day~* Diabetes, liver, kidney, thyroid (unless controlled and stable on replacement medication) or other endocrine disorders from self-reported medical history~* Treatment with drugs acting on the gut, such as ezetimibe, bile acid-binding resins, orlistat~* Dietary restrictions such as a medically prescribed diet, or a slimming diet prior to or during the trial~* Weight loss or gain of 10% body weight or more during a period of 6 months before pre-study examination.~* Blood/plasma donation for reason(s) other than the present study prior to the study (1 month for a male subject or 2 months for a female subject), or during the study~* Lactation 6 weeks before the start of and during study, pregnant or wishing to become pregnant 3 months before or during the study

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Whole walnut (Type: EXPERIMENTAL): 85g whole walnuts, ground, incorporated into inert food carrier
- Walnut meat (Type: EXPERIMENTAL): Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
- Walnut oil (Type: EXPERIMENTAL): Walnut oil extracted from nut meat and incorporated into inert food carrier
- Walnut skins (Type: EXPERIMENTAL): Separated, ground walnut skins incorporated into inert food carrier

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - Men and women with type 2 diabetes mellitus - Age above or equal to 50 years at screening and clinical evidence of cardiovascular disease or age above or equal to 60 years at screening and subclinical evidence of cardiovascular disease - Anti-diabetic drug naïve, or treated with one or two oral antidiabetic drug (OADs), or treated with human Neutral Protamin Hagedorn (NPH) insulin or long-acting insulin analogue or pre-mixed insulin, both types of insulin either alone or in combination with one or two OADs - HbA1c above or equal to 7.0% at screening Exclusion Criteria: - Type 1 diabetes mellitus - Use of glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide, or other) or pramlintide within 90 days prior to screening - Use of any dipeptidyl peptidase 4 (DPP-IV) inhibitor within 30 days prior to screening - Treatment with insulin other than basal and pre-mixed insulin within 90 days prior to screening - except for short-term use in connection with intercurrent illness - Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (eg diabetes ketoacidosis) within 90 days prior to screening - History of chronic pancreatitis or idiopathic acute pancreatitis - Acute coronary or cerebro-vascular event within 90 days prior to randomisation - Currently planned coronary, carotid or peripheral artery revascularisation - Chronic heart failure New York Heart Association (NYHA) class IV - Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma - Personal history of non-familial medullary thyroid carcinoma - Screening calcitonin above or equal to 50 ng/L

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 0.5 mg (Type: EXPERIMENTAL): None
- Semaglutide 1.0 mg (Type: EXPERIMENTAL): None
- Semaglutide placebo 0.5 mg (Type: PLACEBO_COMPARATOR): None
- Semaglutide placebo 1.0 mg (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient who has histologically confirmed and newly diagnosed breast cancer~* Patient who has clinical stage I, II, or IIIa operable breast cancer according to AJCC (American Joint Committee on Cancer) Breast Cancer Staging 7th edition~* Patient who has HER2-positive status confirmed locally, defined as 3+ score by IHC (immuno-histochemistry).~Exclusion Criteria:~* Patient who has bilateral breast cancer~* Patient who has received prior treatment for breast cancer, including chemotherapy, biologic therapy, hormone therapy, immunotherapy, radiation or surgery, including any prior therapy with anthracyclines.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CT-P6 (Type: EXPERIMENTAL): None
- Trastuzumab (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Clinical Criteria~* Male or non-pregnant female ≥18 years of age.~* Rutherford Clinical Category 2-5~* Patient is willing to provide informed consent and comply with the required follow up visits, testing schedule, and medication regimen Angiographic Criteria~* A single de novo or restenotic atherosclerotic lesion \>70% in the SFA or popliteal artery that is ≥4 cm and ≤15 cm in total length.~* Reference vessel diameter ≥4 mm and ≤ 6mm~* Successful wire crossing of lesion~* A patent inflow artery free from significant lesion (\>50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of inflow artery lesions)~Exclusion Criteria:~* Pregnant or planning on becoming pregnant in \< 2yrs~* Live expectancy of \<2 years~* Patient actively participating in another investigational device or drug study~* History of hemorrhagic stroke within 3 months~* Previous or planned surgical or interventional procedure within 30 days of index procedure~* Chronic renal insufficiency with creatinine \>2.5 mg/L~* Prior surgery of the target lesion~* Inability to take required study medications~* Anticipated use of IIb/IIIa inhibitor prior to randomization~* Lesion length is \<4 cm or \>15 cm or there is no normal proximal arterial segment in which duplex ultrasound velocity ratios can be measured~* Known inadequate distal outflow~* Significant inflow disease~* Acute or sub-acute thrombus in target vessel~* Severe lesion calcification~* Acute vessel occlusion or sudden symptom onset~* Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.)~* Prior participation in the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lutonix Catheter (Type: EXPERIMENTAL): Paclitaxel coated Balloon Catheter
- Standard uncoated Balloon Angioplasty Catheter (Type: ACTIVE_COMPARATOR): uncoated angioplasty balloon

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daytime Corneal Swelling During Wear of Narafilcon B Lenses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Be of legal age (i.e. ≥ 18 years).~* Be mentally competent, willing and able to sign a written informed consent form.~* Have contact lens distance sphere requirement in the range -1.00D to -6.00D.~* Have spectacle astigmatism \<1.25D in each eye.~* Currently wear soft contact lenses (for at least 6 months prior to the trial) with documentation of current prescription.~* Have normal eyes with no evidence of abnormality or disease. For the purpose of this study a normal eye is defined as one having: i) no evidence of lid abnormality or infection; ii) no conjunctival abnormality or infection; iii) no clinically significant slit lamp findings (i.e, edema, staining, scarring, vascularization, infiltrates or abnormal opacities); iv) no other active ocular disease.~Exclusion Criteria:~* Required concurrent ocular medication.~* Any systemic illness which would contra-indicate lens wear or the medical treatment of which would affect vision or successful lens wear.~* Eye injury or surgery within eight weeks immediately prior to enrollment for this study.~* Abnormal lacrimal secretions.~* Pre-existing ocular irritation that would preclude contact lens fitting.~* Keratoconus or other corneal irregularity.~* Pregnancy, lactating or planning a pregnancy at the time of enrollment.~* Participation in any concurrent clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Spectacles No Lenses (Type: PLACEBO_COMPARATOR): Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
- narafilcon B (Type: EXPERIMENTAL): Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
- polymacon (Type: ACTIVE_COMPARATOR): Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
- lotrafilcon A (Type: ACTIVE_COMPARATOR): Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who in their own and/or in the Investigator's opinion, consider ongoing antipsychotic treatment inadequate, because of insufficient efficacy and/or tolerability.~* Female patients of childbearing potential must have a negative serum pregnancy test at enrolment and be willing to use a reliable method of birth control, ie, barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device, or tubal ligation during the study.~* Able to understand and comply with the requirements of the study, as judged by the Investigator.~Exclusion Criteria:~* Meeting the criteria for any other (than schizophrenia) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Axis I diagnosis, concomitant organic mental disorder or mental retardation.~* Substance abuse or dependence as defined by DSM-IV and not in full remission. A urine drug screen test will be performed. The Investigator will evaluate the results along with medical history to determine if the patient meets DSM-IV criteria for substance abuse or dependence.~* Risk of transmitting human immunodeficiency virus (HIV) or hepatitis B, via blood or other body fluids, as judged by the Investigator.~* Patients who, in the opinion of the Investigator, pose an imminent risk of suicide or a danger to self or others.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete